Email ID
Password
Scrip   
Blinatumomab rights return to Micromet
06 November 2009
Christopher Spillane

Micromet has agreed to buy out MedImmune's (AstraZeneca) rights to blinatumomab (MT103) in North America, which will give it back global rights to develop and commercialise the antibody.

The agreement ends the companies' six-year collaboration for blinatumomab and returns to Micromet the...



Please Login to read the full article.
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36